Scholarlink

<p>Recent estimates point to roughly 49 million cases and 11–13 million deaths annually due to sepsis, with a disproportionate burden borne by low- and middle-income countries. Three decades of progress, summarised in the recently updated Surviving Sepsis Campaign guidelines, have refined how clinicians screen for, resuscitate, and treat patients with sepsis. Yet, persistent uncertainty surrounds early identification, pathogen detection, hemodynamic targets, adjunctive therapies, and the long-term burden carried by survivors. This Collection, Sepsis: Treatment, intervention, mortality, brings together original research that maps where the field is moving: pragmatic diagnostics that run on standard hospital equipment; multi-omic biomarker discovery in blood, plasma extracellular vesicles, and urine; computational dissection of pathogen biology and longitudinal host-response trajectories; preclinical interrogation of metabolic and signalling pathways implicated in organ injury; and mechanistic studies of the muscle and mitochondrial wasting that shape life after sepsis. Together, these papers sketch a research agenda for sepsis that is simultaneously molecularly precise and operationally scalable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Closing the sepsis gap: from molecular mechanisms to scalable bedside care

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Luis Felipe Reyes,
  • Krzysztof Laudanski

摘要

Recent estimates point to roughly 49 million cases and 11–13 million deaths annually due to sepsis, with a disproportionate burden borne by low- and middle-income countries. Three decades of progress, summarised in the recently updated Surviving Sepsis Campaign guidelines, have refined how clinicians screen for, resuscitate, and treat patients with sepsis. Yet, persistent uncertainty surrounds early identification, pathogen detection, hemodynamic targets, adjunctive therapies, and the long-term burden carried by survivors. This Collection, Sepsis: Treatment, intervention, mortality, brings together original research that maps where the field is moving: pragmatic diagnostics that run on standard hospital equipment; multi-omic biomarker discovery in blood, plasma extracellular vesicles, and urine; computational dissection of pathogen biology and longitudinal host-response trajectories; preclinical interrogation of metabolic and signalling pathways implicated in organ injury; and mechanistic studies of the muscle and mitochondrial wasting that shape life after sepsis. Together, these papers sketch a research agenda for sepsis that is simultaneously molecularly precise and operationally scalable.